<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Problems of Virology</journal-id><journal-title-group><journal-title xml:lang="en">Problems of Virology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы вирусологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0507-4088</issn><issn publication-format="electronic">2411-2097</issn><publisher><publisher-name xml:lang="en">Central Research Institute for Epidemiology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">16710</article-id><article-id pub-id-type="doi">10.36233/0507-4088-288</article-id><article-id pub-id-type="edn">ukfplk</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL RESEARCHES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The results of the detection of specific IgG antibodies to Ebola virus (Filoviridae: <italic>Orthoebolavirus</italic>) in residents of the Republic of Guinea after the end of the epidemic</article-title><trans-title-group xml:lang="ru"><trans-title>Результаты выявления специфических антител класса IgG к возбудителю болезни, вызванной вирусом Эбола (Filoviridae: <italic>Orthoebolavirus</italic>), у жителей Гвинейской Республики после завершения эпидемии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6474-3696</contrib-id><name-alternatives><name xml:lang="en"><surname>Naidenova</surname><given-names>Ekaterina V.</given-names></name><name xml:lang="ru"><surname>Найденова</surname><given-names>Екатерина Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Biology), Leading Researcher at the Department of Diagnostics of Infectious Diseases</p></bio><bio xml:lang="ru"><p>канд. биол. наук, ведущий научный сотрудник отдела диагностики инфекционных болезней </p></bio><email>katim2003@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7857-6822</contrib-id><name-alternatives><name xml:lang="en"><surname>Kartashov</surname><given-names>Mikhail Yu.</given-names></name><name xml:lang="ru"><surname>Карташов</surname><given-names>Михаил Юрьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Biology), Senior Researcher at the Department of Flavivirus Infections </p></bio><bio xml:lang="ru"><p>канд. биол. наук, старший научный сотрудник отдела флавивирусных инфекций </p></bio><email>Mikkartash@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6850-338X</contrib-id><name-alternatives><name xml:lang="en"><surname>Shulgina</surname><given-names>Irina S.</given-names></name><name xml:lang="ru"><surname>Шульгина</surname><given-names>Ирина Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Junior Researcher at the Collection of Microorganisms Department</p></bio><bio xml:lang="ru"><p>младший научный сотрудник отдела коллекции микроорганизмов </p></bio><email>Shuigina.is@vector.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6593-6614</contrib-id><name-alternatives><name xml:lang="en"><surname>Pyankov</surname><given-names>Stepan A.</given-names></name><name xml:lang="ru"><surname>Пьянков</surname><given-names>Степан Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Senior Researcher at the Collection of Microorganisms Department </p></bio><bio xml:lang="ru"><p>ведущий научный сотрудник отдела коллекции микроорганизмов </p></bio><email>pyanstep@gmail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6423-1460</contrib-id><name-alternatives><name xml:lang="en"><surname>Kulagin</surname><given-names>Maxim A.</given-names></name><name xml:lang="ru"><surname>Кулагин</surname><given-names>Максим Андреевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Junior Researcher at the Department of Diagnostics of Infectious Diseases </p></bio><bio xml:lang="ru"><p>младший научный сотрудник отдела диагностики инфекционных болезней </p></bio><email>rusrapi@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4565-269X</contrib-id><name-alternatives><name xml:lang="en"><surname>Bah</surname><given-names>Mamadou B.</given-names></name><name xml:lang="ru"><surname>Ба</surname><given-names>Мамадю Бандикура</given-names></name></name-alternatives><address><country country="GN">Guinea</country></address><bio xml:lang="en"><p>Researcher</p></bio><bio xml:lang="ru"><p>научный сотрудник</p></bio><email>boundoukhourabah@gmail.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2970-9676</contrib-id><name-alternatives><name xml:lang="en"><surname>Nourdine</surname><given-names>Ibrahim</given-names></name><name xml:lang="ru"><surname>Нурдин</surname><given-names>Ибрагим</given-names></name></name-alternatives><address><country country="GN">Guinea</country></address><bio xml:lang="en"><p>PhD (Biology), Researcher, Director</p></bio><bio xml:lang="ru"><p>канд. биол. наук, научный сотрудник, директор</p></bio><email>Ibrahimndin@yahoo.fr</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3760-6642</contrib-id><name-alternatives><name xml:lang="en"><surname>N’Fally</surname><given-names>Magassouba</given-names></name><name xml:lang="ru"><surname>Н’Фалли</surname><given-names>Магассуба</given-names></name></name-alternatives><address><country country="GN">Guinea</country></address><bio xml:lang="en"><p>PhD (Biology), Scientific Consultant</p></bio><bio xml:lang="ru"><p>канд. биол. наук, научный консультант</p></bio><email>cmagassouba01@gmail.com</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-5010-0041</contrib-id><name-alternatives><name xml:lang="en"><surname>Konomou</surname><given-names>Viktor</given-names></name><name xml:lang="ru"><surname>Коному</surname><given-names>Виктор</given-names></name></name-alternatives><address><country country="GN">Guinea</country></address><bio xml:lang="en"><p>Chief Physician of the Hospital </p></bio><bio xml:lang="ru"><p>главный врач госпиталя </p></bio><email>Saet-64@yandex.ru</email><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3811-8675</contrib-id><name-alternatives><name xml:lang="en"><surname>Traore</surname><given-names>Mohamed S.</given-names></name><name xml:lang="ru"><surname>Траоре</surname><given-names>Мамед Заар</given-names></name></name-alternatives><address><country country="GN">Guinea</country></address><bio xml:lang="en"><p>PhD (Biology), Director General </p></bio><bio xml:lang="ru"><p>канд. биол. наук, Генеральный директор </p></bio><email>dg@irbag.edu.gn</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4506-6033</contrib-id><name-alternatives><name xml:lang="en"><surname>Boumbaly</surname><given-names>Sanaba</given-names></name><name xml:lang="ru"><surname>Бумбали</surname><given-names>Санаба</given-names></name></name-alternatives><address><country country="GN">Guinea</country></address><bio xml:lang="en"><p>PhD (Biology), Director </p></bio><bio xml:lang="ru"><p>канд. биол. наук, директор </p></bio><email>drboumbaly@yahoo.fr</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3788-3452</contrib-id><name-alternatives><name xml:lang="en"><surname>Kutyrev</surname><given-names>Vladimir V.</given-names></name><name xml:lang="ru"><surname>Кутырев</surname><given-names>Владимир Викторович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr Sci (Medicine), Academician of the Russian Academy of Sciences, Professor, Director </p></bio><bio xml:lang="ru"><p>академик РАН, д-р мед. наук, профессор, директор </p></bio><email>rusrapi@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian Research Anti-Plague Institute «Microbe» of the Federal Service for Surveillance of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)</institution></aff><aff><institution xml:lang="ru">ФКУН Российский научно-исследовательский противочумный институт «Микроб» Роспотребнадзора</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">State Scientific Center of Virology and Biotechnology «Vector» of the Federal Service for Surveillance of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)</institution></aff><aff><institution xml:lang="ru">ФБУН «Государственный научный центр вирусологии и биотехнологии «Вектор» Роспотребнадзора</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Research Institute of Applied Biology of Guinea</institution></aff><aff><institution xml:lang="ru">Исследовательский институт прикладной биологии Гвинеи</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Virological Research Center, Laboratory of Viral Hemorrhagic Fevers of Guinea</institution></aff><aff><institution xml:lang="ru">Лаборатория вирусных геморрагических лихорадок</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Scientific Clinical and Diagnostic Center of Epidemiology and Microbiology</institution></aff><aff><institution xml:lang="ru">Научный клинико-диагностический центр эпидемиологии и микробиологии</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-04-30" publication-format="electronic"><day>30</day><month>04</month><year>2025</year></pub-date><volume>70</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>154</fpage><lpage>163</lpage><history><date date-type="received" iso-8601-date="2025-01-14"><day>14</day><month>01</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Naidenova E.V., Kartashov M.Y., Shulgina I.S., Pyankov S.A., Kulagin M.A., Bah M.B., Nourdine I., N’Fally M., Konomou V., Traore M.S., Boumbaly S., Kutyrev V.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Найденова Е.В., Карташов М.Ю., Шульгина И.С., Пьянков С.А., Кулагин М.А., Ба М.Б., Нурдин И., Н’Фалли М., Коному В., Траоре М.З., Бумбали С., Кутырев В.В.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Naidenova E.V., Kartashov M.Y., Shulgina I.S., Pyankov S.A., Kulagin M.A., Bah M.B., Nourdine I., N’Fally M., Konomou V., Traore M.S., Boumbaly S., Kutyrev V.V.</copyright-holder><copyright-holder xml:lang="ru">Найденова Е.В., Карташов М.Ю., Шульгина И.С., Пьянков С.А., Кулагин М.А., Ба М.Б., Нурдин И., Н’Фалли М., Коному В., Траоре М.З., Бумбали С., Кутырев В.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://virusjour.crie.ru/jour/article/view/16710">https://virusjour.crie.ru/jour/article/view/16710</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> In 2014–2016, an epidemic of Ebola virus disease (EVD) was registered in Guinea. In 2021, EVD cases were repeated in the region. The importance of studying the duration of post-infection immunity to the Ebola virus in the body of convalescents is due to the fact that after the end of the epidemic they can be the main sources of infection. One of the indicators of the pathogen circulation in a certain area is the detection of specific IgG antibodies in the blood sera of the inhabitants.</p> <p><bold>The aim</bold> of the study is to identify IgG immunoglobulins to Ebola virus in the blood sera of reconvalescents and practically healthy residents of the Republic of Guinea after the end of the epidemic.</p> <p><bold>Materials and methods. </bold>The ELISA method was used to test the blood sera of 9 patients treated at the NKDCEM hospital (Kindia), collected after the end of the disease and up to 72 months after recovery, and 3939 blood serum samples from practically healthy residents of Guinea.</p> <p><bold>Results. </bold>IgG antibodies in the blood sera of reconvalescents a month after recovery were detected in a titer of up to 1 : 800. By 12 months, the antibody level decreased to 1 : 100 and remained at this level for up to 48 months. After 6 years of observation, no antibodies were registered. Among the 3939 blood samples from healthy residents, IgG immunoglobulins to the Ebola virus were detected in 5.6%. Most of the positive samples were collected in Forest Guinea (7.7%), and a smaller part in Upper Guinea (4.5%). The maximum percentage of positive samples was detected in people over 70 years of age (12.3%).</p> <p><bold>Conclusion. </bold>In our case, it was shown that a high level of post-infection immunity in the blood sera of patients with EVD persists for the first 6 months, this corresponds to the data obtained by other authors, and does not exclude the possibility of re-infection. The highest level of the seroprevalence is registered in Forest Guinea. This indicates the active circulation of the pathogen and the constant contact of the inhabitants of the region with it, which leads to epidemiological complications.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> В 2014–2016 гг. на территории Гвинеи была зарегистрирована эпидемия болезни, вызванной вирусом Эбола (БВВЭ). В 2021 г. случаи БВВЭ в регионе повторились. Важность изучения длительности постинфекционного иммунитета к вирусу Эбола в организме реконвалесцентов обусловлена тем, что после завершения эпидемии эти лица могут являться основными источниками заражения. Один из показателей циркуляции возбудителя на определенной территории – обнаружение специфических иммуноглобулинов класса G (IgG) в сыворотках крови населения.</p> <p><bold>Цель</bold> работы – выявление антител класса IgG к вирусу Эбола в сыворотках крови переболевших и практически здоровых жителей Гвинейской Республики после завершения эпидемии.</p> <p><bold>Материалы и методы.</bold> Методом иммуноферментного анализа протестированы сыворотки крови 9 пациентов, проходивших лечение в госпитале НКДЦЭМ (г. Киндиа, Гвинея), взятые после окончания болезни и до 72 мес после выздоровления, и 3939 проб крови практически здоровых жителей Гвинеи.</p> <p><bold>Результаты.</bold> Антитела класса IgG в сыворотках крови переболевших через месяц после выздоровления выявляли в титре до 1 : 800. К 12 мес уровень антител снизился до 1 : 100 и держался на таком уровне до 48 мес. После 72 мес наблюдений антитела не регистрировались. Из 3939 образцов крови здоровых жителей антитела класса IgG к вирусу Эбола выявлены в 5,6%. Бо́льшая часть положительных образцов собрана в Лесной Гвинее (7,7%), а меньшая – в Верхней (4,5%). Максимальное количество позитивных проб выявлено у лиц старше 70 лет (12,3%).</p> <p><bold>Заключение.</bold> В настоящем исследовании высокий уровень постинфекционного иммунитета в сыворотках крови переболевших БВВЭ сохранялся первые 6 мес, что соответствует данным, полученным другими авторами, и не исключает возможность повторного заражения. Самый высокий уровень иммунной прослойки населения зарегистрирован в Лесной Гвинее. Это может свидетельствовать об активной циркуляции возбудителя и постоянном контакте с ним жителей региона, что приводит к эпидемиологическим осложнениям.</p></trans-abstract><kwd-group xml:lang="en"><kwd>IgG class immunoglobulins</kwd><kwd>Ebola virus disease</kwd><kwd>Ebola virus</kwd><kwd>immune layer</kwd><kwd>Republic of Guinea</kwd><kwd>ELISA</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>иммуноглобулины класса IgG</kwd><kwd>болезнь, вызванная вирусом Эбола</kwd><kwd>вирус Эбола</kwd><kwd>иммунная прослойка</kwd><kwd>Гвинейская Республика</kwd><kwd>иммуноферментный анализ</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Gonzalez J.P., Herbreteau V., Morvan J., Leroy E.M. Ebola virus circulation in Africa: a balance between clinical expression and epidemiological silence. Bull. Soc. Pathol. Exot. 2005; 98(3): 210–7.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Malvy D., McElroy A.K., de Clerck H., Günther S., van Griensven J. Ebola virus disease. Lancet. 2019; 393(10174): 936–48. https://doi.org/10.1016/S0140-6736(18)33132-5</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Keita A.K., Koundouno F.R., Faye M., Düx A., Hinzmann J., Diallo H., et al. Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks. Nature. 2021; 597(7877): 539–43. https://doi.org/10.1038/s41586-021-03901-9</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Pare B.C., Camara A.M., Camara A., Kourouma M., Enogo K., Camara M.S., et al. Ebola outbreak in Guinea, 2021: Clinical care of patients with Ebola virus disease. S. Afr. J. Infect. Dis. 2023; 38(1): 454. https://doi.org/10.4102/sajid.v38i1.454</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Kritsky A.A., Keita S., Magassouba N., Krasnov Ya.M., Safronov V.A., Naidenova E.V., et al. Ebola virus disease outbreak in the Republic of Guinea 2021: hypotheses of origin. bioRxiv. Preprint. 2021. https://doi.org/10.1101/2021.04.23.440924</mixed-citation></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Lopatin A.A., Naidenova E.V., Safronov V.A., Razdorsky A.S., Utkin D.V., Kas’Yan Zh.A., et al. Studies of Ebola Virus persistence in the Body Fluids of a Patient at Advanced Stages of Convalescence. Problemy osobo opasnykh infektsii. 2015; (3): 73–6. https://doi.org/10.21055/0370-1069-2015-3-73-76 (in Russian)</mixed-citation><mixed-citation xml:lang="ru">Лопатин А.А., Найденова Е.В., Сафронов В.А., Раздорский А.С., Уткин Д.В., Касьян Ж.А. и др. Изучение сохранения вируса Эбола в биологических жидкостях пациента на поздних стадиях выздоровления. Проблемы особо опасных инфекций. 2015; (3): 73–6. https://doi.org/10.21055/0370-1069-2015-3-73-76</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><mixed-citation>Diallo B., Sissoko D., Loman N.J., Bah H.A., Bah H., Worrell M.C., et al. Resurgence of Ebola virus disease in Guinea linked to a survivor with virus persistence in seminal fluid for more than 500 days. Clin. Infect. Dis. 2016; 63(10): 1353–6. https://doi.org/10.1093/cid/ciw601</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Geisbert T.W. Persistence of Ebola virus RNA in seminal fluid. Lancet Glob. Health. 2017; 5(1): e12–3. https://doi.org/10.1016/S2214-109X(16)30336-9</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Mukadi-Bamuleka D., Edidi-Atani F., Morales-Betoulle M.E., Legand A., Nkuba-Ndaye A., Bulabula-Penge J., et al. Fatal meningoencephalitis associated with Ebola virus persistence in two survivors of Ebola virus disease in the Democratic Republic of the Congo: a case report study. Lancet Microbe. 2024; 5(10): 100905. https://doi.org/10.1016/S2666-5247(24)00137-X</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Fallah M.P., Reilly C., Van Ryn C., Badio M., Camanor S.W., Kaler S.G., et al. Pregnancy, pregnancy outcomes, and infant growth and development after recovery from Ebola virus disease in Liberia: an observational cohort study. Lancet Glob. Health. 2023; 11(7): e1053–60. https://doi.org/10.1016/S2214-109X(23)00210-3</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Baize S., Leroy E.M., Georges-Courbot M.C., Capron M., Lansoud-Soukate J., Debré P., et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 1999; 5(4): 423–6. https://doi.org/10.1038/7422</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Natesan M., Jensen S.M., Keasey S.L., Kamata T., Kuehne A.I., Stonier S.W., et al. Human survivors of disease outbreaks caused by Ebola or Marburg virus exhibit cross-reactive and long-lived antibody responses. Clin. Vaccine Immunol. 2016; 23(8): 717–24. https://doi.org/10.1128/CVI.00107-16</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Rimoin A.W., Lu K., Bramble M.S., Steffen I., Doshi R.H., Hoff N.A., et al. Ebola virus neutralizing antibodies detectable in survivors of the Yambuku, Zaire outbreak 40 years after infection. J. Infect. Dis. 2018; 217(2): 223–31. https://doi.org/10.1093/infdis/jix584</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Diallo M.S.K., Ayouba A., Keita A.K., Thaurignac G., Sow M.S., Kpamou C., et al. Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study. Lancet Microbe. 2021; 2(12): e676–84. https://doi.org/10.1016/S2666-5247(21)00170-1</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Gonzalez J.P., Josse R., Johnson E.D., Merlin M., Georges A.J., Abandja J., et al. Antibody prevalence against haemorrhagic fever viruses in randomized representative Central African populations. Res. Virol. 1989; 140(4): 319–31. https://doi.org/10.1016/s0923-2516(89)80112-8</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Busico K.M., Marshall K.L., Ksiazek T.G., Roels T.H., Fleerackers Y., Feldmann H., et al. Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic Republic of the Congo, 1995. J. Infect. Dis. 1999; 179(Suppl. 1): S102–7. https://doi.org/10.1086/514309</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Rowe A.K., Bertolli J., Khan A.S., Mukunu R., Muyembe-Tamfum J.J., Bressler D., et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. J. Infect. Dis. 1999; 179(Suppl. 1): S28–35. https://doi.org/10.1086/514318</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Becquart P., Wauquier N., Mahlakõiv T., Nkoghe D., Padilla C., Souris M., et al. High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS One. 2010; 5(2): e9126. https://doi.org/10.1371/journal.pone.0009126</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Bouree P., Bergmann J.F. Ebola virus infection in man: a serological and epidemiological survey in the Cameroons. Am. J. Trop. Med. Hyg. 1983; 32(6): 1465–6. https://doi.org/10.4269/ajtmh.1983.32.1465</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Gonzalez J.P., Nakoune E., Slenczka W., Vidal P., Morvan J.M. Ebola and Marburg virus antibody prevalence in selected populations of the Central African Republic. Microbes Infect. 2000; 2(1): 39–44. https://doi.org/10.1016/s1286-4579(00)00287-2</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Bane S., Rosenke K., Maiga O., Feldmann F., Meade-White K., Callison J., et al. Ebola virus IgG seroprevalence in Southern Mali. Emerg. Infect. Dis. 2021; 27(6): 1681–4. https://doi.org/10.3201/eid2706.203510</mixed-citation></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Ivanov A.P., Tkachenko E.A., van der Groesen G., Butenko A.M., Konstantinov O.K. Indirect enzyme immunoassay for laboratory diagnosis of hemorrhagic Lassa fever and Ebola. Voprosy virusologii. 1986; 31(2): 186–90. (in Russian)</mixed-citation><mixed-citation xml:lang="ru">Иванов А.П., Ткаченко Е.А. ван дер Гроен Г., Бутенко А.М., Константинов О.К. Непрямой иммуноферментный метод для лабораторной диагностики геморрагических лихорадок Ласса и Эбола. Вопросы вирусологии. 1986; 31(2): 186–90.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Butenko A.M. Retrospective data on the study of Ebola virus in Africa. Epidemiologiya i infektsionnye bolezni. 2015; 20(1): 39–43. https://elibrary.ru/ttmbcv (in Russian)</mixed-citation><mixed-citation xml:lang="ru">Бутенко А.М. Ретроспективные данные по изучению лихорадки Эбола в Африке. Эпидемиология и инфекционные болезни. 2015; 20(1): 39–43. https://elibrary.ru/ttmbcv</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Popova A.Yu., Smolensky V.Yu., Naidenova E.V., Shcherbakova S.A., Safronov V.A., Kolomoets E.V., et al. Russia – Guinea: Historical Aspects of Scientific Cooperation in the Fight against Dangerous Infectious Diseases. Problemy osobo opasnykh infektsii. 2024; (3): 6–14. https://doi.org/10.21055/0370-1069-2024-3-6-14 (in Russian)</mixed-citation><mixed-citation xml:lang="ru">Попова А.Ю., Смоленский В.Ю., Найденова Е.В., Щербакова С.А., Сафронов В.А., Коломоец Е.В. и др. Россия – Гвинея: исторические аспекты научного взаимодействия в области борьбы с опасными инфекционными болезнями. Проблемы особо опасных инфекций. 2024; (3): 6–14. https://doi.org/10.21055/0370-1069-2024-3-6-14</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">P’yankov S.A., P’yankov O.V., Naydenova E.V., Agafonov A.P., Boiro M.Y., Solodkiy V.V., et al. Experience of application of the Elisa method for detection of antibodies to Ebola virus during the Saet team work in the Republic of Guinea. Problemy osobo opasnykh infektsii. 2016; (3): 71–5. https://elibrary.ru/xantbd (in Russian)</mixed-citation><mixed-citation xml:lang="ru">Пьянков С.А., Пьянков О.В., Найденова Е.В., Агафонов А.П., Boiro M.Y., Солодкий В.В. и др. Опыт использования метода ИФА для выявления антител к вирусу Эбола при работе бригады СПЭБ в Гвинейской Республике. Проблемы особо опасных инфекций. 2016; (3): 71–5. https://elibrary.ru/xantbd</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><mixed-citation>Dean N.E., Halloran M.E., Yang Y., Longini I.M. Transmissibility and pathogenicity of Ebola virus: a systematic review and meta-analysis of household secondary attack rate and asymptomatic infection. Clin. Infect. Dis. 2016; 62(10): 1277–86. https://doi.org/10.1093/cid/ciw114</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Bower H., Glynn J.R. A systematic review and meta-analysis of seroprevalence surveys of ebolavirus infection. Sci. Data. 2017; 4(1): 160133. https://doi.org/10.1038/sdata.2016.133</mixed-citation></ref></ref-list></back></article>
